← All deals

Cellphire, Inc.

BiotechnologyBiotechnologyTherapeuticsClinical Stage
📍 Rockville, Maryland, United States• Founded 2005• 45 employees
StreetZero Signal 75
Be the first to signal interest

About Cellphire, Inc.

Cellphire Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation therapeutics using proprietary cell stabilization technology applied to platelets. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets with a 3-year shelf stability. The company is advancing Thrombosomes® and Cryopreserved Platelets (CPP) into Phase 2 clinical trials for bleeding patients, targeting markets exceeding $4 billion with applications in trauma, wound care, and regenerative medicine.

LATEST FUNDINGPrivate Placement
$6.5M
Announced 2026-11-16
TOTAL RAISED$21M
🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Cellphire, Inc..

Free plan includes 3 full deal profiles every month.

Key highlights

  • Closed $15M Series A in 2021 led by Simcah Management to fund Phase 2 trials.
  • Lead product Thrombosomes® is the only platelet-based freeze-dried hemostatic in clinical trials.
  • Receives significant funding from U.S. Department of Defense for CPP development.
  • Total funding across rounds reaches $21-25.3M with government backing.
  • Targeting BLA submission for CLPH-511 in 2026.
  • techStack

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account